ASP-8062


ASP-8062, or ASP8062, is a GABAB receptor positive allosteric modulator which is under development for the treatment of alcoholism. It was also under development for the treatment of fibromyalgia and opioid-related disorders, but development for these indications was discontinued. The drug is taken orally.

Pharmacology

It shows analgesic and antiaddictive effects in animals. In a polysomnography study, ASP-8062 dose-dependently enhanced slow wave sleep without affecting REM sleep in humans. It also dose-dependently increased growth hormone release. The time to peak levels of ASP-8062 in humans is 1 to 4hours and its elimination half-life is approximately 40 to 50hours.

Development

ASP-8062 is under development by Astellas Pharma in collaboration with the National Institute on Alcohol Abuse and Alcoholism. As of June 2023, it is in phase 2 clinical trials for alcoholism. The drug is the most advanced GABAB receptor positive allosteric modulator in clinical trials as of 2024.